Cargando…

Gut Microbes Take It to the Next Level? First Insights Into Farnesoid X Receptor Agonists of Microbial Origin

Detalles Bibliográficos
Autores principales:	Lenicek, Martin, Olde Damink, Steven W.M., Schaap, Frank G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Hepatology Elsewhere
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702049/ https://www.ncbi.nlm.nih.gov/pubmed/32648608 http://dx.doi.org/10.1002/hep.31455

Ejemplares similares

Cell-type specific functions of epidermal growth factor receptor are involved in development of hepatocellular carcinoma
por: Timchenko, Nikolai A
Publicado: (2015)

Bis‐choline Tetrathiomolybdate as Old Drug in a New Design for Wilson’s Disease: Good for Brain and Liver?
por: Stremmel, Wolfgang
Publicado: (2018)

Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?
por: Sinha, Rohit A., et al.
Publicado: (2020)

Long‐Term Perfusion of the Liver Outside the Body: Warming Up for Ex Vivo Therapies?
por: Schurink, Ivo J., et al.
Publicado: (2020)

Bile Duct Repair in Human Liver Grafts: Effective Cholangiocyte Organoid Engraftment and Plasticity
por: van der Laan, Luc J.W., et al.
Publicado: (2021)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

The use of vaptan in hyponatremic patients with liver cirrhosis
por: Choe, Won Hyeok
Publicado: (2011)

Body iron, serum ferritin, and nonalcoholic fatty liver disease
por: Shim, Jae-Jun
Publicado: (2012)

Growing attention to an old marker, hepatitis B surface antigen, in the natural history of chronic hepatitis B
por: Jang, Jeong Won
Publicado: (2010)

The effect of sorafenib on hepatic stellate cells: implication of its effect on tumor microenvironment
por: Lee, Jung Il
Publicado: (2010)

Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin
por: Kim, Kyung-Ah
Publicado: (2011)

Role of vitamin D in chronic hepatitis C
por: Kim, Tae Yeob
Publicado: (2011)

Noninvasive diagnosis of hepatocellular carcinoma
por: Kim, Byung Seok
Publicado: (2012)

New Kids on the Block: Bile Salt Conjugates of Microbial Origin
por: Ay, Ümran, et al.
Publicado: (2022)

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Effect of Plasmapheresis on Cholestatic Pruritus and Autotaxin Activity During Pregnancy
por: Heerkens, Marieke, et al.
Publicado: (2019)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
por: Abenavoli, Ludovico, et al.
Publicado: (2020)

Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites
por: Zhang, Xiang, et al.
Publicado: (2021)

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
por: Mori, Hideki, et al.
Publicado: (2022)

Fragile X mental retardation protein protects against tumour necrosis factor-mediated cell death and liver injury
por: Zhuang, Yuan, et al.
Publicado: (2020)

Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner
por: Trivedi, Palak J, et al.
Publicado: (2018)

Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study
por: Erken, Robin, et al.
Publicado: (2021)

The effect of Farnesoid X receptor agonist tropifexor on liver damage in rats with experimental obstructive jaundice
por: Kilavuz, Huseyin, et al.
Publicado: (2021)

Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists
por: Zhao, Shizhen, et al.
Publicado: (2021)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist
por: He, Handan, et al.
Publicado: (2023)

Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism
por: Zhang, Limin, et al.
Publicado: (2016)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis
por: Namisaki, Tadashi, et al.
Publicado: (2017)

Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis
por: Hu, Ying-Bin, et al.
Publicado: (2018)

Assessment of drug–drug interaction potential with EDP‐305, a farnesoid X receptor agonist, in healthy subjects
por: Ahmad, Alaa, et al.
Publicado: (2022)

Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers
por: Younis, Islam R., et al.
Publicado: (2023)

Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis
por: Schramm, Christoph, et al.
Publicado: (2022)

Menstrual blood‐derived mesenchymal stem cells attenuate inflammation and improve the mortality of acute liver failure combining with A2AR agonist in mice
por: Chen, Dazhi, et al.
Publicado: (2021)

Food Microbial Biodiversity and “Microbes of Protected Origin”
por: Capozzi, Vittorio, et al.
Publicado: (2011)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Impact of early life nutrition on gut health in children: a prospective clinical study
por: Ley, Delphine, et al.
Publicado: (2021)

Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects
por: Kechagias, S, et al.
Publicado: (2008)

Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection
por: Deuffic-Burban, S, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_k24tqmdhog15pia2um72ob72rf